Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pivotal Phase 3 Trial of ARQ 087 in FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma
2016-004448-12Phase 3Completed
- Sponsor
- ArQule
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of derazantinib in intrahepatic cholangiocarcinoma (ICC), sponsored by ArQule. Primary endpoint: Objective Response Rate (ORR). Started Feb 2018; status: completed.
02
Drugs
derazantinib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on 2016-004448-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004448-12.